Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Common Equity (2019 - 2025)

Cresco Labs' Common Equity history spans 7 years, with the latest figure at $252.5 million for Q4 2025.

  • For Q4 2025, Common Equity fell 34.95% year-over-year to $252.5 million; the TTM value through Dec 2025 reached $252.5 million, down 34.95%, while the annual FY2025 figure was $252.5 million, 34.95% down from the prior year.
  • Common Equity reached $252.5 million in Q4 2025 per CRLBF's latest filing, down from $388.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $755.6 million in Q4 2021 to a low of $252.5 million in Q4 2025.
  • Average Common Equity over 5 years is $482.4 million, with a median of $428.1 million recorded in 2023.
  • Peak YoY movement for Common Equity: surged 59.66% in 2021, then plummeted 34.95% in 2025.
  • A 5-year view of Common Equity shows it stood at $755.6 million in 2021, then fell by 22.22% to $587.7 million in 2022, then dropped by 27.16% to $428.1 million in 2023, then fell by 9.32% to $388.2 million in 2024, then plummeted by 34.95% to $252.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRLBF's Common Equity are $252.5 million (Q4 2025), $388.2 million (Q4 2024), and $428.1 million (Q4 2023).